COPD in a nationally representative sample: Sociodemographic factors and co-morbidity, diagnosis method, and healthcare utilization

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 1, 2015, Pages 96-103

  Mowls, Dana S ^a   Cheruvu, Vinay K ^a   Schilz, Robert ^b   Zullo, Melissa D ^a  

^a KENT STATE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Behavioral Risk Factor Surveillance System; Breathing test; Race ethnicity; Spirometry

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHMA; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BLACK PERSON; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DEPRESSION; EMERGENCY CARE; EXERCISE; FEMALE; HEALTH CARE UTILIZATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPIROMETRY; CROSS-SECTIONAL STUDY; EMERGENCY HEALTH SERVICE; HEALTH CARE DISPARITY; HEALTH SURVEY; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; CROSS-SECTIONAL STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTHCARE DISPARITIES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; PUBLIC HEALTH SURVEILLANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; UNITED STATES;

EID: 84923072109     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.922065     Document Type: Article

References (42)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-1276.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
3. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System 2012. 2012. Available at: http://www.cdc.gov/brfss/
4. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System, 2003 Summary Data Quality Report. 2004.
5. SAS Institute Inc. 2012. Cary, NC, USA.
6. Li C, Balluz LS, Ford ES, Okoro CA, Zhao G, Pierannunzi C. A comparison of prevalence estimates for selected health indicators and chronic diseases or conditions from the Behavioral Risk Factor Surveillance System, the National Health Interview Survey, and the National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2012; 54:381-387.
7. GOLD. Global strategy for the diagnosis, managemebnt, and prevention of chronic obstructive pulmonary disease. 2012. Available at: http://www.goldcopd.org/
8. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Difference in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418-424.
9. Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW, et al. Burden of concomitant asthma and COPD in a Medicaid population Chest 2008; 134:14-19.
10. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn Diagram of obstructive lung diseases: two approximations from the United States and the United Kingdom. Chest 2003; 124:474-481.
11. de Marco R, Pesce G, Marcon A, Accordini S, Antonicelli L, Bugiani M, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PlosOne 2013; 8:e62985.
12. Behrendt CE. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128:1239-1244.
13. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. Chest 2011; 139:752-763.
14. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366:1875-1881.
15. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Wang X, et al. COPD in Chinese nonsmokers. Eur Respir J 2009; 33:509-518.
16. Zahran HS, Bailey V. Factors Associated with Asthma Prevalence among Racial and Ethnic Groups-United States, 2009-2010 Behavioral Risk Factor Surveillance System. J Asthma 2013; 50:583-589.
17. Zahran HS, Person CJ, Bailey C, Moorman JE. Predictors of asthma self-management education among children and adults-2006-2007 behavioral risk factor surveillance system asthma call-back survey. J Asthma 2012; 49:98-106.
18. Pierannunzi C, Hu SS, Balluz L. A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004-2011. BMC Med Res Methodol 2013; 13:49.
19. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6:320-329.
20. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
21. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta analysis. JAMA 2008; 300:2407-2416.
22. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166.
23. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102:1099-1108.
24. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144-149.
25. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:855-859.
26. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439-1450.
27. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez- Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59:387-395.
28. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
29. Vestbo J. THE TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24:206-210.
30. Joo MJ, LeeTA, Au DH, Fitzgibbon ML, Weiss KB. Medication use patterns associated with spirometry in diagnosing COPD. COPD 2008; 5:360-368.
31. Chavannes N, Schermer T, Akkermans R, Jacobs JE, van de Graaf G, Bollen R, Van SO, Bottema B. Impact of spirometry on GPs' diagnostic differentiation and decision-making. Respir Med 2004; 98:1124-1130.
32. Dales RE, Vandemheen KL, Clinch J, Aaron SD. Spirometry in the primary care setting: influence on clinical diagnosis and management of airflow obstruction. Chest 2005; 128:2443-2447.
33. Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006; 28:945-952.
34. Yawn BP, Enright PL, Lemanske, Jr. RF, Israel E, Pace W, Wollan P, Boushey H. Spirometry can be done in family physicians' offices and alters clinical decisions in management of asthma and COPD. Chest 2007; 132:1162-1168.
35. Mathers C, Boerma T, Ma Fat D. Global Burden of Disease 2004. World Health Organization. 2004; 6-2-2012. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
36. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13:1109-1114.
37. Elixhauser A, Au DH, Podulka J. 2006. Readmissions for Chronic Obstructive Pulmonary Disease, 2008: Statistical Brief #121.
38. American Lung Association. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality. 2013. Available at: http://www.lung.org/fi nding-cures/our-research/trend-reports/copd-trend-report.pdf. Accessed: 06/27/2014
39. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Respir Care 2002; 47:1184-1199.
40. Blair IV, Havranek EP, Price DW, Hanratty R, Fairclough DL, Farley T, Hirsh HK, Steiner JF. Assessment of biases against Latinos and African Americans among primary care providers and community members. Am J Public Health 2013; 103:92-98.
41. Straus SE, McAlister FA, Sackett DL, Deeks JJ. THE accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283:1853-1857.
42. Straus SE, McAlister FA, Sackett DL, Deeks JJ. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med 2002; 17:684-688.